Exenatide and the treatment of patients with Parkinson's disease
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
UNLABELLED: BACKGROUND. There is increasing interest in methods to more rapidly and cost-efficiently investigate drugs that are approved for clinical use in the treatment of another condition. Exenatide is a type 2 diabetes treatment that has been shown to have neuroprotective/neurorestorative properties in preclinical models of neurodegeneration. METHODS. As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls. Their PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), together with several nonmotor tests, at baseline, 6 months, and 12 months and after a further 2-month washout period (14 months). RESULTS. Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient. Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group. Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control patients (P = 0.037). CONCLUSION. These results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD. TRIAL REGISTRATION: Clinicaltrials.gov NCT01174810. FUNDING: Cure Parkinson's Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to preliminary clinical trials, patients treated with exenatide improved by 2.7 points on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) after 12 months, compared to a decline of 2.2 points in control patients. 86”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [86]
In the citing paper
“Another single-blind, phase 2 trial evaluated exenatide, which improved motor deficits in PD patients for more than 12 months.523”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [523]
In the citing paper
“Therefore, diabetes drugs such as GLP-1 are used to treat AD and PD, and have shown good efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
In the citing paper
“Currently, GLP-1 drugs have been used in AD and PD patients in clinical trials and have shown efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“The frequency of the adverse events in the exenatide group was similar to that seen in the previous clinical trials of exenatide in diabetes patients (4, 5).”
BackgroundResultWeaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“The first of these, exendin-4, was discovered in the saliva of the Gila monster (3) and found to have beneficial effects on glucose homeostasis through stimulation of glucose level–dependent insulin release, islet cell proliferation, reduction of islet cell apoptosis, and weight loss (4, 5).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · cited 1×
“8) (23), although this can vary Table 4 Adverse events reported by trial participants”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Cited by
Items 301–400 of 529
Waragai, M., Ho, G. J., Takamatsu, Y., Shimizu, Y., Sugino, H., Sugama, S., Takenouchi, T., Masliah, E., & Hashimoto, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.009 · Cited by 19
“Insulin, glucagon like peptide-1 receptor agonists, and inhibitors of dipeptidyl peptidase 4 have been studied [3–5] with promising results in small-scale trials [3,4], but the results require validation in larger clinical studies.”
BackgroundFan, S., Qiu, Y., Liu, J., Zhu, T., Wang, C., Liu, D., Yan, L., & Ren, M. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16242 · Cited by 21
“Additionally, exenatide use was linked to improvements in Parkinson's rating scales, highlighting the potential benefits of GLP-1RA in the central nervous system (Aviles-Olmos et al., 2013).”
Helal, M. M., AbouShawareb, H., Abbas, O., Haddad, R., Zain, Y. E., Osman, A. S. A., & Hassan, A. K. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01888-1 · Cited by 23
“Differences in base-line characteristics of trial arms may affect intervention response and disease progression [28], potentially impacting or skewing the results of the trials.”
InfluentialWyse, R. K. H., Isaacs, T., Barker, R. A., Cookson, M., Dawson, T. M., Devos, D., Dexter, D. T., Duffen, J., Federoff, H. J., Fiske, B. K., et al. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230363 · Cited by 18
Self-citationEngineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Exenatide – a drug for diabetes and Parkinson disease?
Jankovic, J. J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.140 · Cited by 18
Romeo-Guitart, D., & Casas, C. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.251187 · Cited by 17
“…kinase-3β-targeted therapy for the treatment of glioblastoma (Furuta et al., 2017) and the promising combination of two anti-diabetic drugs that exert neuroprotection in a mouse model of Alzheimer´s disease and in patients with Parkinson disease (Aviles-Olmos et al., 2013; Hettich et al., 2014).”
Brain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET
Deden, L. N., Booij, J., Grandjean, J., Homberg, J. R., Hazebroek, E. J., Gotthardt, M., & Boss, M. (2021) · Brain Sciences · doi:10.3390/brainsci11121647 · Cited by 21
“Moreover, a smaller, open label study showed significant effects on cognition in PD [28].”
BackgroundChai, S., Liu, F., Yu, S., Yang, Z., & Sun, F. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14015 · Cited by 19
Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease
Verma, A., & Goyal, A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176936 · Cited by 18
Protection against neurodegenerative disease on Earth and in space
Takamatsu, Y., Koike, W., Takenouchi, T., Sugama, S., Wei, J., Waragai, M., Sekiyama, K., & Hashimoto, M. (2016) · npj Microgravity · doi:10.1038/npjmgrav.2016.13 · Cited by 17
“(b) Neurodegeneration induced by microgravity may be potentiated by factors such as diabetes, altered behaviors and cosmic rays in space. npj Microgravity (2016) 16013 © 2016 Macmillan Publishers Limited effects of insulin.31 Analogs of GLP-1, such as exenatide and liraglutide, have been shown to be effective in a pil…”
BackgroundThe gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy
Kakoty, V., Sarathlal, K. C., Dubey, S. K., Yang, C. H., Kesharwani, P., & Taliyan, R. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135865 · Cited by 19
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Self-citationO'Brien, J. T., Chouliaras, L., Sultana, J., Taylor, J., Ballard, C. G., on behalf of the RENEWAL Study Group, Aarsland, D., Blanc, F., Boeve, B. F., Brooks, D. J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01103-7 · Cited by 17
“5 point decline respectively in control patients [87].”
BackgroundWu, L., Chu, L., Pang, Y., Huo, J., Cao, H., Tian, Q., & Gao, Q. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01411-1 · Cited by 16
“There is mounting evidence that people with type 2 diabetes are more likely to acquire PD and have similar dysregulated pathways, indicating common pathological under-pinnings [46].”
Prospects of antidiabetic drugs in the treatment of neurodegenerative disease
Hu, L., Wang, W., Chen, X., Bai, G., Ma, L., Yang, X., Shu, Q., & Li, X. (2024) · Brain‐X · doi:10.1002/brx2.52 · Cited by 20
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Yabe, D., Kuwata, H., Usui, R., Kurose, T., & Seino, Y. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1045471 · Cited by 16
Umegaki, H. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0375-0 · Cited by 19
Animal venoms: therapeutic tools for tackling Parkinson’s disease
Amaral, H. D. O., Monge‐Fuentes, V., Mayer, A. B., Campos, G. A. A., Lopes, K. S., Camargo, L. C., Schwartz, M. F., Galante, P., & Mortari, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.004 · Cited by 17
Shang, P., Baker, M. R., Banks, S. A., Hong, S., & Choi, D. (2021) · Journal of Movement Disorders · doi:10.14802/jmd.21035 · Cited by 17
Common pathophysiology affecting diabetic retinopathy and Parkinson’s disease
Tian, T., Li, Z., & Hong, L. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.06.016 · Cited by 15
“Moreover, drugs already in use for insulin resistance also show protective effects in PD, thus possibly being a common link between diabetes and PD [19,24].”
BackgroundDay, S. M., Yang, W., Ewin, S. E., Zhou, X., & Ma, T. (2017) · Hippocampus · doi:10.1002/hipo.22795 · Cited by 19
“As a result, mimics of GLP1 (7–36) or DPP-4 inhibitors have been actively developed to improve its pharmacokinetics and are tested in neurodegenerative diseases (Aviles-Olmos et al., 2013, 2014; Campbell & Drucker, 2013; Gejl et al., 2016; Sandoval & D’Alessio, 2015).”
BackgroundWang, C., Wu, T., Lin, F., Tai, C., Lin, C., & Wu, R. (2021) · European Journal of Neurology · doi:10.1111/ene.15234 · Cited by 16
Ntetsika, T., Catrina, S., & Markaki, I. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01910 · Cited by 20
“Early phase trials on Exenatide have been performed in the UK with positive results on motor symptom progression in PD (Aviles-Olmos et al., 2013; Aviles-Olmos et al., 2014; Athauda et al., 2017) and several others are ongoing including a phase 3 trial in the UK ( Table 1 ).”
Messak, M., Abdelmageed, A., Senbel, A. A., Khattab, Y. A., Mandour, Y., Shaker, O., Rehan, A. H., Oransa, S., Nasr, M., Shabeeb, A. E., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03932-3 · Cited by 20
“Of the included studies, two of them were conducted in the UK (Athauda et al. 2017; Aviles-Olmos et al. 2013), one in the USA (McGarry et al. 2024), and one in France (Meissner et al. 2024) summary of their designs and main results is shown in Table 1 and the baseline characteristics of their…”
Protective Effects of Incretin Against Age-Related Diseases
Zhang, D., Ma, M., & Liu, Y. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191010145029 · Cited by 15
Victorino, D. B., Nejm, M. B., Guimarães‐Marques, M., Scorza, F. A., & Scorza, C. A. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00374-5 · Cited by 19
Rate of motor progression in Parkinson’s disease: a systematic review and meta-analysis
Pauwels, A., Phan, A. L. G., Ding, C., Phan, T. G., & Kempster, P. A. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1452741 · Cited by 15
Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus
Dou, X., Zhao, L., Li, J., & Jiang, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1537898 · Cited by 19
Neuroprotective role of (Val 8 ) GLP-1-Glu-PAL in an in vitro model of Parkinson′s disease
Liu, Y., Li, L., Liu, K., Zhao, J., Hölscher, C., & Li, G. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.177742 · Cited by 15
“Based on these encouraging preclinical studies, a pilot clinical trial of exendin-4 was conducted in patients with Parkinson’s disease (Aviles-Olmos et al., 2013).”
InfluentialNovel approaches to counter protein aggregation pathology in Parkinson's disease
Stott, S., Wyse, R. K. H., & Brundin, P. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.007 · Cited by 16
Self-citationAssociation Between Pathophysiological Mechanisms of Diabetic Retinopathy and Parkinson’s Disease
Zhang, Z., Zhou, Y., Zhao, H., Xu, J., & Yang, X. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00953-9 · Cited by 16
Khalilnezhad, A., & Taşkıran, D. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1543671 · Cited by 15
Fraternine, a Novel Wasp Peptide, Protects against Motor Impairments in 6-OHDA Model of Parkinsonism
Mayer, A. B., de Oliveira, D. G. R., Amaral, H. D. O., Campos, G. A. A., Gonçalves, J. C., de Souza, A. C. B., Lima, M. R., Silva, L. P., & Mortari, M. R. (2020) · Toxins · doi:10.3390/toxins12090550 · Cited by 16
Gandhi, A., & Parhizgar, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1708565 · Cited by 18
“That said, for patients with T2DM or obesity who are also at high risk for neurodegeneration, choosing a GLP-1RA might offer the potential for ancillary neuroprotection, though we must await de fi nitive phase 3 outcomes before making such claims (4 – 6, 22, 23).”
Dahiya, S., Tisch, S. H., & Greenfield, J. R. (2022) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2022.100133 · Cited by 13
Parkinson’s Disease and Diabetes Mellitus: Synergistic Effects on Pathophysiology and GI Motility
Yan, Y., Shimoga, D., & Sharma, A. (2023) · Current Gastroenterology Reports · doi:10.1007/s11894-023-00868-7 · Cited by 14
The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
Ribarič, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084358 · Cited by 18
Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson’s Disease
Jeong, S. H., & Lee, P. H. (2025) · Journal of Movement Disorders · doi:10.14802/jmd.25008 · Cited by 13
“26 Furthermore, a phase IIb clinical trial successfully met its primary endpoint, showing a significant reduction in the progression of motor symptoms, as assessed by the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III, following 48 weeks of double-blind…”
Gamborg, M., Grand, M. K., Arvedsen, J., Meaidi, A., & Mørch, L. S. (2025) · European Journal of Neurology · doi:10.1111/ene.70075 · Cited by 13
“Exenatide has demonstrated sustained motor benefits and potential disease-modifying effects in two trials [6, 7], while liraglutide [8] has also shown improvements in daily living and motor disability.”
Au, H. C. T., Lam, P. H., Lim, P. K., & McIntyre, R. S. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106159 · Cited by 20
Insulin and disorders of behavioural flexibility
Sullivan, M., Fernández‐Aranda, F., Camacho‐Barcia, L., Harkin, A., Macrì, S., Mora‐Maltas, B., Jiménez‐Múrcia, S., O’Leary, A., Ottomana, A. M., Presta, M., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105169 · Cited by 17
“A recent meta-analysis of antidiabetic agents for the treatment of Parkinson’s disease suggests that treatment with the diabetes medication exenatide is associated with the alleviation of cognitive, motor and nonmotor symptoms (18).”
BackgroundRecent Advances in Drug Repurposing for Parkinson’s Disease
Chen, X., Gumina, G., & Virga, K. G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180719144850 · Cited by 15
Lowering the risk of Parkinson’s disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes
Bayram, E., & Litvan, I. (2020) · Brain · doi:10.1093/brain/awaa287 · Cited by 15
Etiology and Pathogenesis of Parkinson Disease
deSouza, R., & Schapira, A. H. V. (2017) · Wiley eBooks · doi:10.1002/9781118661895.ch5 · Cited by 14
Drug repositioning for Parkinson’s disease: An emphasis on artificial intelligence approaches
Karimi-Sani, I., Sharifi, M., Abolpour, N., Lotfi, M., Atapour, A., Takhshid, M. A., & Sahebkar, A. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102651 · Cited by 14
A new approach to disease-modifying drug trials in Parkinson’s disease
Barker, R. A., Stacy, M. A., & Brundin, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69690 · Cited by 12
“Address correspondence to: Patrik Brun-din, Center for Neurodegenerative Science, Van Andel Institute, 333 Bostwick allel group of patients that were matched to those in the treatment arm, but did not receive any injectable therapy (1).”
InfluentialKhan, M. A., Haider, N., Singh, T., Bandopadhyay, R., Ghoneim, M. M., Alshehri, S., Taha, M., Ahmad, J., & Mishra, A. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01180-z · Cited by 13
“Exenatide was well-tolerated, with the primary side effect being weight reduction, which had no bearing on the trial's conclusion (Aviles-Olmos et al. 2013).”
BackgroundGlucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
“This led to pilot studies showing improvements in motor and cognitive function in people with Parkinson’s disease [76] and also Alzheimer’s disease.”
Zhang, Y., Wang, C., Wang, Y., & Wang, T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13301-y · Cited by 12
Bashir, B., Vishwas, S., Gupta, G., Paudel, K. R., Dureja, H., Kumar, P., Cho, H., Sugandhi, V. V., Kumbhar, P., Disouza, J., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102693 · Cited by 11
Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 15
Xie, Y., Wang, J., Jiang, J., Liu, F., & Zhang, Y. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06965-9 · Cited by 11
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease
Santiago, J. A., & Potashkin, J. A. (2014) · Diagnostics · doi:10.3390/diagnostics4040153 · Cited by 11
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
Inaishi, J., & Saisho, Y. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288846 · Cited by 14
“Although it is unclear how to improve motor symptoms for patients with Parkinson’s disease, exenatide is expected to have neuroprotective effects in this disease and other neurodegenerative disorders.(59) Thus, further verification of the effects of exenatide QWon children and adults with T2DM or obesity, as well as p…”
BackgroundAΙ-Driven Drug Repurposing: Applications and Challenges
Keramida, P., Syrigos, N. K., Kouvela, M., Poulakou, G., Charpidou, A. G., & Fiste, O. (2025) · Medicines · doi:10.3390/medicines12040028 · Cited by 14
“Data from clinical trials support that exenatide ameliorates the mobility dysfunction in PD patients [190,191].”
Greco, M., Munir, A., Musarò, D., Coppola, C., & Maffia, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1244022 · Cited by 10
Anwar, M. M., Pérez‐Martínez, L., & Pedraza‐Alva, G. (2024) · Immunological Investigations · doi:10.1080/08820139.2024.2358446 · Cited by 11
Shestakova, M. V., Vikulova, O. K., Zheleznyakova, A. V., Kutakova, D. V., Исаков, М. А., & Mokrysheva, N. G. (2025) · Diabetes Mellitus · doi:10.14341/dm13261 · Cited by 10
Alhomoud, I. S., Wheeler, S. E., & Dixon, D. L. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0038 · Cited by 14
Avilés-Olmos, I., Espinoza‐Vinces, C., Portugal, L. R., & Luquin, M. R. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01606-1 · Cited by 14
“While some studies have demon - strated changes in insulin signaling pathways and neuro - trophic markers, others have failed to detect meaningful alterations in dopaminergic imaging [32 , 34 , 54, 55, 61].”
InfluentialHarkavyi, A., Rampersaud, N., & Whitton, P. S. (2013) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/407152 · Cited by 14
Self-citationTang, Y., Yang, K., Zhao, J., Liang, X., & Wang, J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00456 · Cited by 10
Kong, Y., Zhou, H., Feng, H., Zhuang, J., Wen, T., Zhang, C., Sun, B., Wang, J., & Guan, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00682 · Cited by 10
Venoms As an Adjunctive Therapy for Parkinson’s Disease: Where are We Now and Where are We going?
Gazerani, P. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0119 · Cited by 12
“A proof-of-concept, single-blind study with 45 moderate PD patients improved the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) score after 12 months of treatment with twice-daily injections of exendin-4 [75].”
BackgroundRodríguez‐Violante, M., & Cervantes‐Arriaga, A. (2014) · Archivos de Neurociencias · doi:10.31157/an.v19i3.50 · Cited by 38
Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases
Hölscher, C. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.01.007 · Cited by 15
The Role of Insulin and Incretins in Neuroinflammation and Neurodegeneration
(2015) · Immunoendocrinology · doi:10.14800/ie.391 · Cited by 12
“Phase two clinical trials demonstrate improvement in motor skills and cognition of PD patients given subcutaneous exenatide injections [79] .”
BackgroundNeuroprotection in Parkinson Disease
Gonzalez‐Robles, C., Bandmann, O., & Schapira, A. H. V. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00793-z · Cited by 12
“…(ER) for‑ mulation, is the GLP‑1 receptor agonist with the broadest clinical evidence, including motor and cognitive improvements in an open‑label phase 2 study [161] which persisted 12 months after drug withdrawal [162], as well as motor improvement in a placebo‑controlled phase 2 trial [163].”
Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy
Vijiaratnam, N., Girges, C., Wiegand, M., Ismail, C., Lameirinhas, A., Yarnall, A. J., Kirk, C., Del‐Din, S., Rochester, L., Kobylecki, C., et al. (2025) · Annals of Neurology · doi:10.1002/ana.70004 · Cited by 11
Self-citationPathologic and Therapeutic Schwann Cells
Shurin, M. R., Wheeler, S., Zhong, H. M., & Zhou, Y. (2025) · Cells · doi:10.3390/cells14171336 · Cited by 11
Understanding the progression of Parkinson’s disease: a review
Kempster, P. A. (2025) · BMJ Neurology Open · doi:10.1136/bmjno-2025-001215 · Cited by 9
Ghaleb, J., Khouzami, K. K., Nassif, N., Attieh, P., Ajlani, M. F. A., Sleiman, J. B., Khalouf, A., Harb, F., Azar, S. T., Kanaan, A., et al. (2025) · International Journal of Endocrinology · doi:10.1155/ije/2876156 · Cited by 11
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Fang, S., Cui, F., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102511 · Cited by 12
Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection
McGrath, R. T. (2015) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000.152 · Cited by 9
“Exenatide was well tolerated and patients in the treated group showed a significant reduction in disease progression and improvements in motor and cognitive skills [90].”
BackgroundPolymer-based Vehicles for Therapeutic Peptide Delivery
Zhang, J., Desale, S. S., & Bronich, T. K. (2015) · Therapeutic Delivery · doi:10.4155/tde.15.71 · Cited by 10
Acting Before; A Combined Strategy to Counteract the Onset and Progression of Dementia
Pizzi, S. D., Granzotto, A., Bomba, M., Frazzini, V., ONOFRJ, M. C., & Sensi, S. L. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201203085524 · Cited by 10
Schmidt, M. R., Ebert, M. L., Kiechle, M. A., Zöller, K., Laffleur, F., & Bernkop‐Schnürch, A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125711 · Cited by 9
The brain-joint axis: links between osteoarthritis and neurodegenerative disorders in aging
Rabie, M. A., Madry, H., Cucchiarini, M., & Sayed, N. S. E. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.023 · Cited by 17
Martins, A. C., de la Torre, B. G., & Alberício, F. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00039 · Cited by 11
New hope for devastating neurodegenerative disease
Stayte, S., & Vissel, B. (2017) · Brain · doi:10.1093/brain/awx064 · Cited by 8
A Research Update on Exendin-4 as a Novel Molecule Against Parkinson’s Disease
Singh, N. K., Singh, A., Varshney, M., & Agrawal, R. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230529093314 · Cited by 10
Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?
Bagnoli, E., & FitzGerald, U. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14115 · Cited by 10
Song, D., Zou, X., Ma, D., Zhao, Y., Liu, T., Shen, B., & Cheng, O. (2025) · Advanced Science · doi:10.1002/advs.202417664 · Cited by 10
Glucagon‐like Peptides (GLP‐1) Perspectives in Synucleinopathies Treatment
Foltynie, T., & Athauda, D. S. (2018) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12611 · Cited by 9
“There was also less decline in cognitive performance.(6) Furthermore, when reassessed the next year, after stopping the exenatide, the previously observed advantages were maintained.”
BackgroundSelf-citationFire prevention in the Parkinson’s disease brain
Brundin, L., Bergkvist, L., & Brundin, P. (2018) · Nature Medicine · doi:10.1038/s41591-018-0109-4 · Cited by 9
Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation
Wasim, R., Ansari, T. M., Siddiqui, M. H., Ahsan, F., Shamim, A., Singh, A. N., Shariq, M., Anwar, A., Siddiqui, A. R., & Parveen, S. (2023) · Hormone and Metabolic Research · doi:10.1055/a-1971-6965 · Cited by 7
“Although this study was not placebo-controlled, blinded ratings showed clinical improvement in exenatide-treated patients, compared to controls [62].”
ResultIon transporter cascade, reactive astrogliosis and cerebrovascular diseases
Rahman, M. S., Islam, R., & Bhuiyan, M. I. H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1374408 · Cited by 10
Efficacy of glucagon-like peptide-1 mimetics for neural regeneration
Sango, K., & Utsunomiya, K. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.169611 · Cited by 7
“A single-blinded clinical trial with 45 PD patients revealed that the treatment with Ex-4 significantly improved the cognition and memory of patients (Aviles-Olmos et al., 2013).”
Athauda, D. S., Evans, J. R., Mahoney‐Sanchez, L., Virdi, G. S., Lopez-Garcia, P., Wernick, A. I., Wagen, A. Z., D’Sa, K., Lachica, J., Strohbuecker, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.28.582460 · Cited by 8
Self-citationTargeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment
Duţă, C., Muscurel, C., Dogaru, C. B., & Stoian, I. A.-M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041516 · Cited by 8
“In 2013, Aviles-Olmos et al. [116] published the results of a single-blind trial using Exenatide for 12 months in 45 patients with moderate Parkinson’s disease.”
Badran, A., & Gbreel, M. I. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08411-4 · Cited by 7
Metformin Attenuates Manganese-Induced Oxidative Stress in N27-A Dopaminergic Neuronal Cells
Kim, J., Seo, J.-Y., Kang, K., Lim, H., Kim, D. K., & Chun, H. S. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00703 · Cited by 8
De, S., Banerjee, S., Rakshit, P., Banerjee, S., & Kumar, S. K. A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291968240429111357 · Cited by 9
Frailty and Parkinson’s disease: the role of diabetes mellitus
Komici, K., Pansini, A., Bencivenga, L., Rengo, G., Pagano, G., & Guerra, G. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1377975 · Cited by 6
“A preliminary data analysis reported that diabetic patients treated with GLP1R agonists had a significant improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with a mean decline of 2.2 points in control patients ( p = 0.037) (96).”
BackgroundInfluentialPresent and future of disease-modifying therapies in multiple system atrophy
Cuina, M. L., Foubert‐Samier, A., Tison, F., & Meissner, W. G. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2017.12.008 · Cited by 6
Disease modifying therapies for Parkinson's disease: Novel targets
Vijiaratnam, N., & Foltynie, T. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108839 · Cited by 7
Self-citationSobral, M. V. S., Soares, V. G., Moreira, J. L. D. M. L., Rodrigues, L. K., Rocha, P., Bendaham, L. C. A. R., Gonçalves, O. R., Pirolla, R. D. C., Vilela, L. V., de Abreu, V. S., et al. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107210 · Cited by 6
Is Exenatide the Next Big Thing in Parkinson's Disease?
Simuni, T., & Brundin, P. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-149001 · Cited by 6
“and co-workers [2] report on a 24-month follow-up of the previously published pilot study of injections of exenatide (which contains exendin-4) as a potential disease-modifying intervention in PD [3].”
BackgroundResult
Metadata
- Authors
- Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., & Foltynie, T.
- Affiliations
- University College London Hospitals NHS Foundation Trust (GB)
- UCL Queen Square Institute of Neurology (GB)
- UCL School of Pharmacy (GB)
- Cure Parkinson's Trust (GB)
- Corresponding author
- Foltynie, Thomas
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-05-20
- Volume
- 123
- Issue
- 6
- Pages
- 2730-2736
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3668846
- OpenAlex
- W2123319002
- Cited by
- 529
- References
- 25
- Citations by year
- 2026: 40 · 2025: 64 · 2024: 56 · 2023: 30 · 2022: 38 · 2021: 36 · 2020: 33 · 2019: 30 · 2018: 39 · 2017: 33 · 2016: 40 · 2015: 36 · 2014: 38 · 2013: 15
- FWCI
- 27.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research
- University College London Hospitals NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- exenatide, Parkinson's disease, drug repurposing, GLP-1 receptor agonists, neuroprotection, disease-modifying therapy, MDS-UPDRS, motor symptoms, cognitive function, non-motor symptoms, weight loss
- MeSH terms
- Exenatide, Aged, Antiparkinson Agents, Constipation, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Motor Activity, Parkinson Disease, Peptides, Venoms, Weight Loss, Disease Progression, Off-Label Use, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.